Study design and participants
AML, dysplasia, CMML after failure, MDS/MPN, Cancer
DYSPLASIA, AML, MUTANT, SECONDARY AML, CANCER
This was a single-center, phase 1/2 study to assess the efficacy and safety of the combination of azacitidine, venetoclax and pevonedistat in patients with newly diagnosed secondary AML or in MDS or CMML after failure of hypomethylating agents. This study was conducted at a single academic center (The University of Texas MD Anderson Cancer Center [UTMDACC]).For the AML cohort, patients were required to have newly diagnosed AML with a history of MDS, MPN or MDS/MPN, MDS-related cytogenetics (other than del9q), morphological dysplasia in ≥ 50% cells in ≥ 2 myeloid lineage (unless accompanied by mutant 